anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will receive the standard of care (SOC) with no neoadjuvant prior to surgery. Following surgical resection, high-risk participants will receive standard radiotherapy plus Cisplatin 100 mg/m\^2 via intravenous infusion on Day 1, every 3 weeks (Q3W) for three 21-day cycles. Low-risk participants will receive only standard radiotherapy.
PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition which accelerates the differentiation of a mammalian chondrocyte by using a hyaluronic acid or a physiologically permissible salt thereof as the effective constituent. SOLUTION: This composition accelerates the production of at least type II collagen and proteoglycan in the process of differentiation of a mammalian chondrocyte, and it also accelerates the differentiation of the chondrocyte. The hyaluronic acid used may be in free acid form or in the form of a physiologically permissible salt thereof. Hyaluronic acids that can be widely used without limitation to the origin in particular comprise those having high purity and neither exhibiting cell damage nor interfering with the use for medicines due to contained impurities such as protein and endotoxin. The molecular weight thereof may be about 200,000 to 2,500,000. Examples of the physiologically permissible salts of hyaluronic acids include alkali metal salts, such as sodium salts and potassium salts, which are usually contained in the human body fluids.  This composition is usually prepared in liquid form.
Pediatric patients in the PCV group(n=30) received pressure-controlled ventilation. The initial parameters will be as follows: the peak inspiratory pressure (PIP) will set to provide a tidal volume of 7 ml/kg , respiratory rate will be 16 breaths/min, inspiratory to expiratory ratio was 1:2 with an upper limit of PIP of 20 cm H2O.
Routine standard care. If glucose \<90 mg/dl and hypoglycemia prediction score \>35, then report for investigators will be collected, but no active alert will be sent to teams.
PURPOSE:To produce a large quantity of callus-inducing cells having high saponin or lignan content in high efficiency by using a medium added with 1-20w/v% of glucose and/or sucrose. CONSTITUTION:A cut tissue piece such as leaf of a plant of genus Bupleurum, family Oenanthe (e.g. Bupleurum falcatum) or genus Schizandra, family Magnoliaceae (e.g. Schizandra chinensis) is sterilized. The sterilized tissue piece is placed on a solid medium produced by adding agar or gelan gum, etc., to a medium containing inorganic components (e.g. nitrogen or phosphorus), 1-20w/v% of sugars consisting of glucose and/or sucrose, a plant growth regulator such as indoleacetic acid (IAA), vitamins such as biotin and natural substances such as hydrolyzed casein and solidifying the mixture. The piece is cultured on the medium under aerobic condition at about 25 deg.C for 3-8hr. Saponins or lignans usable as pharmaceuticals can be produced by this process in large quantity at a low cost.
Modified viruses are prepd. from vertebrates by incubating a suspension of the virus with yeast cells in a culture medium, (esp. Saccharomyces cerevisiae). Process ensures destruction of viral or tumoral genetic matl. which may render dangerous any vaccine prepd. from the virus. The process may be applied to adenovirus; herpes, vaccinia, Rous sarcoma, poliomyelitis, rabies, measles, influenza, Newcastle disease and hepatitis viruses. Prefd. incubation conditions are 35 degrees C for 72-120h. at pH 6-8. Attenuation of the virus is achieved by formation of a new nucleoprotein from viral nucleic acid and protein from the host cells.
Pancreatic cancer is characterized by a densely fibrotic stroma. The fibrotic stroma hinders the intratumoral penetration of nanomedicine and diminishes therapeutic efficacy. Fibrosis is characterized by an abnormal organization of extracellular matrix (ECM) components, namely the abnormal deposition and/or orientation of collagen and fibronectin. Abnormal ECM organization is chiefly driven by pathological signaling in pancreatic stellate cells (PSCs), the main cell type involved in fibrogenesis. However, whether targeting signaling pathways involved in abnormal ECM organization improves the intratumoral penetration of nanomedicines is unknown. Here, we show that targeting transforming growth factor-β (TGFβ)/Rho-associated kinase (ROCK) 1/2 signaling in PSCs normalizes ECM organization and concomitantly improves macromolecular permeability of the fibrotic stroma. Using a 3-dimensional cell culture model of the fibrotic pancreatic cancer microenvironment, we found that pharmacological inhibition of TGFβ or ROCK1/2 improves the permeation of various macromolecules. By using an isoform-specific pharmacological inhibitor and siRNAs, we show that targeting ROCK2, but not ROCK1, alone is sufficient to normalize ECM organization and improve macromolecular permeability. Moreover, we found that ROCK2 inhibition/knockdown attenuates Yes-associated protein (YAP) nuclear localization in fibroblasts co-cultured with pancreatic cancer cells in 3D. Finally, pharmacological inhibition or siRNA-mediated knockdown of YAP normalized ECM organization and improved macromolecular permeability. Our results together suggest that the TGFβ/ROCK2/YAP signaling axis may be therapeutically targeted to normalize ECM organization and improve macromolecular permeability to augment therapeutic efficacy of nanomedicines in pancreatic cancer.
1486706 Finishing yarns JOHNSON & JOHNSON 25 Nov 1975 [26 Nov 1974] 48374/75 Headings D1F and D1W Dental floss or tape 10 comprises a twisted or twistless, perhaps coloured, multifilament or staple fibre core thread 11 impregnated and coated with water-insoluble wax 13 containing spray-dried flavour particles 12 which occur on the surface of, or partially embedded in, the wax as well as throughout the filaments. The latter may be of nylon, rayon, polyethylene terephthalate cellulose acetate, polypropylene, cotton or wool. The wax, which may comprise 19-25% by weight of the floss, is preferably white or colourless with a melting point of 140-200‹F e.g. beeswax, paraffin and microcrystalline wax, polyethylene glycols, wax-like resins and polymers, and mixtures thereof. The particles consist of a flavour oil e.g. peppermint, cassia, cinnamon fruits, disposed in a watersoluble matrix material e.g. gums such gum acacia, arabic or tragacanth, starches such as corn starch, or dextrin. In forming the floss the thread is passed through a molten dispersion of the wax and particles to be impregnated &c. therewith, and the thread is thereafter cooled to set the wax.
These patients are tested positive for C13-urea breath test (C13-UBT) and negative for H. pylori Saliva Test Cassette (HPS),they are given PPI quadruple therapy for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT will be performed to confirm the results of gastric H. pylori eradication.At the same time, Patients with successful eradication will be instructed to conduct 13C-UBT examination after 1year to confirm whether the recurrence of gastric H. pylori.
A system and method for treating hoof related diseases, particularly hairy heel warts (papillomatus digital dermatitis), includes an aqueous solution having a metal astringent at a therapeutically effective concentration. The metal astringent includes aluminum, iron, and mixtures thereof. In preferred embodiments, the metal may include a mixture of monomeric and polymeric species. The polymeric species may be in the form of a polymeric concentrate, such as, for example, polyaluminum chloride or polyferric sulfate. Alternatively, the polymeric species may be formed by partially neutralizing a metal salt. The aqueous solution of the metal astringent is applied to a lower leg and hoof area of an animal using any known application technique, including, but not limited to, foot baths, foams and spray applications. In preferred embodiments, the aqueous solution is applied using an automated dispensing system. The aqueous solution may include additional components, such as surfactants and thickeners, to enhance the performance of the metal astringent or contribute additional functionality.
Respiratory diseases are a significant healthcare burden worldwide. In Canada, this is expected to increase. Non-invasive medical imaging tests are able to provide regional functional and structural information of the lung and may aid in the diagnosis and treatment of respiratory diseases. Current examples include chest x-ray, x-ray computed tomography (CT), and nuclear medicine techniques. However, these techniques suffer from various associated limitations. X-ray based methods offer high resolution and rapid acquisitions, but only reflect lung structure and anatomy by measuring tissue density. Nuclear medicine techniques may be used to measure lung function but suffer from poor resolution and long acquisition times. Furthermore, both x-ray based and nuclear medicine imaging techniques make use of ionizing radiation, which may not be suitable for longitudinal imaging, or imaging in vulnerable populations such as children.

Conventional Magnetic Resonance Imaging (MRI) images the 1H nucleus (proton) attached to water molecules in biological tissues. MRI can provide high-resolution anatomical and functional information of the lung with multiparametric contrast without the use of ionizing radiation. However, major drawbacks associated with conventional 1H MRI of the lung are the low tissue density, large magnetic susceptibility differences between numerous air/tissue interfaces, and image corruption by cardiorespiratory motion during the necessarily long image acquisition time frame. Wo;;

One strategy which may be employed to overcome the limitations associated with conventional 1H MRI is the application of safe MR-sensitive inhaled tracer gases. This allows for the direct visualization of the spatial distribution of these gases, revealing regional ventilation directly. In this study we aim to develop, implement, and test these technologies for improved in-vivo imaging of lung structure and function in adults and children with no history of respiratory disease.
Twenty (20) healthy adult subjects will be injected with \[64Cu\]FBP8 to establish the safety, whole body distribution, metabolism, pharmacokinetics, and radiation burden of the probe. All subjects will be imaged using PET/MR. Healthy subjects will undergo blood collection before, during, and after the scan. Healthy subjects will also undergo electrocardiogram before and after the scan. An interim review of the data will be conducted after the first six subjects receive the study agent and complete all safety assessments.
Patients receive atezolizumab IV over 30-60 minutes on day 1. Patients also receive temozolomide PO QD on days 1-14 of cycle 1 and days 1-21 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The present invention provides an oil controlling composition and an oil controlling cream containing the same. The oil controlling composition contains: 1-5 parts by weight of silicon dioxide; 2-10 parts by weight of hydrated silicon dioxide; and 10-15 parts by weight of emulsifier. The weight ratio of silicon dioxide to hydrated silicon dioxide is 1:2. The oil controlling cream contains: 63-77 parts by weight of water; 1-5 parts by weight of silicon dioxide; 2-10 parts by weight of hydrated silicon dioxide; 10-15 parts by weight of emulsifier; 7-9 parts by weight of polyglycerol and/or polyglycerol derivatives; and 0.1-0.3 parts by weight of preservative. The weight ratio of silicon dioxide to hydrated silicon dioxide is 1:2. By using the aforementioned oil controlling composition and oil controlling cream containing the same, the problems that the skin feels thick and easily get flakey when conventional cosmetic products are applied on user's face can be solved.
PURPOSE: To prepare an aqueous solution, transparent and stable even after cooling and useful as a pharmaceutical and a cosmetic compositions by thermally mixing a salt of primycin with an adequate amount of pyroglutamic acid in isopropanol, diluting the prepared mixture with water and then stirring the resultant diluted solution under heating. CONSTITUTION: This stable aqueous solution of primycin is prepared by suspending primycin sulfate in an amount of 0.5-1.75% (wt./vol.) based on the volume of the solution to be prepared or a complex of the primycin in an amount of 2.5-9% (wt./vol.) based on the volume of the solution to be prepared with N-methylpyrrolidone and pyroglutamic acid (preferably L-glutamic acid) or its soluble salt (especially Na salt) in an amount of 2-15% (wt./vol.) based on the volume of the solution to be prepared in isopropanol in a volume of 40-60vol.% based on the volume of the solution to be prepared under stirring and heating (preferably at 40-60 deg.C), diluting the resultant mixture to a desired concentration with water and stirring and cooling the obtained emulsionlike suspension. A complex containing 20wt.% primycin with the N- methylpyrrolidone is preferably used.
BACKGROUND: Background epidemiologic population data from low- and middle-income countries (LMIC), on maternal, foetal and neonatal adverse outcomes are limited. We aimed to estimate the incidence of maternal, foetal and neonatal adverse outcomes at South African maternal vaccine trial sites as reported directly in the clinical notes as well as using the 'Global Alignment of Immunization Safety Assessment in Pregnancy' case definitions (GAIA-CDs). GAIA-CDs were utilized as a tool to standardise data collection and outcome assessment, and the applicability and utility of the GAIA-CDs was evaluated in a LMIC observational study.
METHODS: We conducted a retrospective record review of maternity and neonatal case records for births that occurred in Soweto, Inner City- Johannesburg and Metro-East Cape Town, South Africa, between 1st July 2017 and 30th June 2018. Study staff abstracted data from randomly selected medical charts onto standardized study-specific forms. Incidence (per 100,000 population) was calculated for adverse maternal, foetal and neonatal outcomes, which were identified as priority outcomes in vaccine safety studies by the Brighton Collaboration and World Health Organization. Outcomes reported directly in the clinical notes and outcomes which fulfilled GAIA-CDs were compared. Incidence of outcomes was calculated by combining cases which were either reported in clinical notes by attending physicians and/ or fulfilled GAIA-CDs.
FINDINGS: Of 9371 pregnant women enrolled, 27·6% were HIV-infected, 19·9% attended antenatal clinic in the 1st trimester of pregnancy and 55·3% had ≥1 ultrasound examination. Fourteen percent of women had hypertensive disease of pregnancy, 1·3% had gestational diabetes mellitus and 16% experienced preterm labour. There were 150 stillbirths (1·6%), 26·8% of infants were preterm and five percent had microcephaly. Data available in clinical notes for some adverse outcomes, including maternal- & neonatal death, severe pre-eclampsia/ eclampsia, were able to fulfil GAIA-CDs criteria for all of the clinically-reported cases, however, missing data required to fulfil other GAIA-CD criteria (including stillbirth, gestational diabetes mellitus and gestational hypertension) led to poor correlation between clinically-reported adverse outcomes and outcomes fulfilling GAIA-CDs. Challenges were also encountered in accurately ascertaining gestational age.
INTERPRETATION: This study contributes to the expanding body of data on background rates of adverse maternal and foetal/ neonatal outcomes in LMICs. Utilization of GAIA-CDs assists with alignment of data, however, some GAIA-CDs require amendment to improve the applicability in LMICs.
FUNDING: This study was funded by Pfizer (Inc).
Cardiac surgery becomes a life-saving option in patients once medical treatments become inadequate. In order to achieve optimal perioperative and long- term success in cardiac surgery, drug treatment should be managed precisely. Patients with cardiovascular diseases are at risk for developing drug related problems (DRPs) due to polypharmacy and having received high-alert medications, such as antiarrhythmics or antithrombotic agents. In addition, type of operation (multiple artery bypass or combined valve procedures), existence of chronic atherosclerotic diseases (such as diabetes mellitus, hypertension), length of stay (LOS) at hospital, frailty, changes in medications for unstable cardiac conditions, incomplete or inadequate history for medication at hospital admission, transition between wards by different healthcare teams and transfer of discrepancies throughout entire perioperative period contributes to increased risk of DRPs in patients at cardiac surgery. It has been shown that over one third of patients suffer from DRPs during hospitalization. Clinical pharmacists are in a position to identify and prevent DRPs, therefore can help to provide optimal pharmaceutical treatment by performing medication reconciliation, improving patient compliance, monitoring of laboratory values and conducting patient education for surgical patients.However, there is limited information about prevalence and risk factors of DRPs in patients at cardiac surgery, in particular with perioperative stages. Majority of studies regarding DRPs have been conducted in specific populations such as elderly, pediatrics or in general medicine. Therefore this study was aimed to determine prevalence, types and associated factors of drug related problems (DRPs) at both preoperative and postoperative stages in patients at cardiac-surgery by using risk analysis method.
BACKGROUND: Overweight and obesity are increasing at epidemic levels in all ages globally, but there is little nationally representative data on female adolescents in Nigeria. The focus on female adolescents is important because of the negative implications of overweight and obesity on their health and survival, and that of their unborn children.
AIM: To estimate the prevalence and identify the determinants of overweight and obesity among female adolescents in Nigeria.
METHODS: Cross-sectional study using data from the Nigeria demographic and health survey, 2018. A total of 2,721 female adolescents aged 15-19 years were selected using cluster sampling technique. Overweight and obesity were determined using BMI-for-age reference values of World Health Organization and different explanatory variables at the individual, household and community levels were included. Binary logistic regression analysis was used to identify the determinants of overweight/obesity using five models.
RESULTS: The mean age of the respondents was 16.8 ± 1.4 years. The prevalence rate of overweight/obesity was 10.2%, but with a large variation in the geographical and socio-economic distribution. At the crude/unadjusted rate, nearly all the explanatory variables showed a statistically significant association with overweight and obesity, but at the full model which controlled for all the explanatory variables, only the household wealth index retained its statistically significant association, such that female adolescents who were from richer and richest households had about 3 times higher odds of being obese compared to those from the poorest households. (OR: 2.7; p = 0.018; CI: 1.18-6.18), (OR: 2.8; p = 0.027; CI: 1.13-7.06) respectively.
CONCLUSION: The prevalence of overweight/obesity among female adolescents in Nigeria was 10.2%. The household wealth index remained the only factor with a statistically significant association with overweight and obesity after controlling for confounders. Efforts at addressing overweight and obesity among female adolescents in Nigeria should target those from the richer/richest households.
PURPOSE:To obtain the titled powder, readily wettable with water, hardly settling and suitable as water-based ink for writing utensils, liquid cosmetic, liquid painting material, water-based magnetic ink, etc., by adsorbing an alkali metal silicate on the surface thereof. CONSTITUTION:The aimed powder obtained by adsorbing an alkali metal silicate, e.g. sodium salt of metasilicic acid, orthosilicic acid, disilicic acid, tetrasilicic acid, etc., on the surface of powder, e.g. organic or inorganic pigment, metal, metal oxide, extender pigment, resin powder, etc. Furthermore, the amount of the alkali metal silicate is preferably 5-200pts.wt. based on 100pts.wt. powder.
Intracytoplasmic sperm injection (ICSI) is one of the standard clinical treatments for infertility. ICSI involves the injection of a single sperm into an oocyte with a sharp micropipette. Injecting a sperm with DNA fragmentation (i.e., physical breakage of the DNA double strands) into the oocyte deterministically lowers the IVF fertilization rate \[1\]\[2\] and increases the miscarriage rate \[3\]\[4\]. Patients with high sperm DNA fragmentation suffer from repeated IVF failures \[8\], causing heavy burdens on families and the healthcare system. Since the invention of ICSI in 1992, single sperm selection in ICSI has been made manually by embryologists, who select sperm by qualitatively choosing sperm with "good" motility and/or morphology based on their empirical experience. This involves significant subjectivity and inconsistency.

We have developed a robotic system to select sperm with low sperm DNA fragmentation. Automated sperm selection also eliminates the subjectivity and inconsistency in manual sperm selection. The system consists of a camera to acquire images of sperm and a software to analyze the images. The software automatically measures the 9 motility parameters (e.g., curvilinear speed, path linearity, etc.) and 11 morphology parameters (e.g., head ellipticity, midpiece width etc.). All these 20 parameters are defined by the WHO guidelines \[9\]. Embryologists select sperm by observing the same sperm characteristics as in the software criteria (e.g., speed etc.), but the software provides a more accurate and quantitative measure of sperm characteristics, thus ensuring the selected sperm have low DNA fragmentation.
Background: Metastasis is the leading cause of death for gastric carcinoma (GC). Currently, GC prognosis is primarily determined based on the clinical data and pathological stages of patients at the time of diagnosis and treatment. However, successful management of GC patients is still hampered by lack of highly sensitive and specific biomarkers capable of predicting prognosis and likelihood of metastasis. GFRA1 hypomethylation along with SRF and ZNF382 hypermethylation were found to be potential synergistic biomarkers for the prediction of GC metastasis in our previous multi-center study. In addition, p16 and E-cadherin were also correlated with GC metastasis in Chinese cohort. To investigate the predictive value of those genes' methylation on metastasis potential in GC, we carried out the prospective cohort study.

Methods: 198 early stage GC patients without lymph node or distal metastasis were included in the present study. Baseline information of E-cadherin, GFRA1, p16, SRF and ZNF382 methylation status of the GC from 191 cases was obtained by MethyLight. The follow-up examination was carried out in a double-blind study with a 6-month interval. The association between gene methylation and metastasis of GC was analyzed with SPSS16.0 software. All P-values were two-sided.